Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.

Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, Kenner L, Sordella R.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15535-40. doi: 10.1073/pnas.1009472107. Epub 2010 Aug 16.

2.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
3.

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.

Jänne PA.

Lung Cancer. 2008 Jun;60 Suppl 2:S3-9. doi: 10.1016/S0169-5002(08)70099-0. Review.

PMID:
18513582
4.

Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.

Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K.

Respir Investig. 2014 Mar;52(2):82-91. doi: 10.1016/j.resinv.2013.07.007. Epub 2013 Aug 30. Review.

PMID:
24636263
5.
6.

[The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant non-small cell lung cancer].

Yamaoka T, Ohmori T.

Gan To Kagaku Ryoho. 2012 Jun;39(6):857-62. Review. Japanese.

PMID:
22705678
7.

Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.

Kosaka T, Yamaki E, Mogi A, Kuwano H.

J Biomed Biotechnol. 2011;2011:165214. doi: 10.1155/2011/165214. Epub 2011 Jun 2. Review.

8.

Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.

Xu Y, Liu H, Chen J, Zhou Q.

Cancer Biol Ther. 2010 Apr 15;9(8):572-82. Epub 2010 Apr 26. Review.

PMID:
20404520
9.

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.

Suda K, Mizuuchi H, Maehara Y, Mitsudomi T.

Cancer Metastasis Rev. 2012 Dec;31(3-4):807-14. doi: 10.1007/s10555-012-9391-7. Review.

PMID:
22736441
10.

Review. EGFR mutations in non-small cell lung cancer--clinical implications.

Charpidou A, Blatza D, Anagnostou V, Syrigos KN.

In Vivo. 2008 Jul-Aug;22(4):529-36. Review. Erratum in: In Vivo. 2008 Nov-Dec;22(6):886. Anagnostou, Elsa [corrected to Anagnostou, Valsamo].

11.

Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.

Dediu M, Median D, Alexandru A, Vremes G, Gal C.

J BUON. 2007 Sep;12 Suppl 1:S137-49. Review.

PMID:
17935272
12.

Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.

Landi L, Minuti G, D'Incecco A, Cappuzzo F.

Curr Opin Oncol. 2013 Mar;25(2):130-6. doi: 10.1097/CCO.0b013e32835daf37. Review.

PMID:
23385860
13.

Epithelial Mesenchymal Transition in Aggressive Lung Cancers.

Mittal V.

Adv Exp Med Biol. 2016;890:37-56. doi: 10.1007/978-3-319-24932-2_3. Review.

PMID:
26703798
14.

Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy.

Ji H.

Cancer Sci. 2010 Sep;101(9):1933-8. doi: 10.1111/j.1349-7006.2010.01629.x. Review.

15.

Predicting the outcome of chemotherapy for lung cancer.

Rosell R, Cecere F, Santarpia M, Reguart N, Taron M.

Curr Opin Pharmacol. 2006 Aug;6(4):323-31. Epub 2006 Jun 12. Review. Erratum in: Curr Opin Pharmacol. 2007 Feb;7(1):119.

PMID:
16765644
16.

Other signalization targets.

Girard N.

Target Oncol. 2013 Mar;8(1):69-77. doi: 10.1007/s11523-012-0246-5. Epub 2013 Jan 10. Review.

PMID:
23307186
17.

Signaling pathways modulating dependence of lung cancer on mutant epidermal growth factor receptor and mechanisms of intrinsic and acquired resistance to tyrosine kinase inhibitors.

Wannesson L, Viteri S, Costa C, Karachaliou N, Molina-Vila MA, Rosell R.

Curr Pharm Des. 2014;20(24):3883-93. Review.

PMID:
24138718
18.

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.

Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, Eyzaguirre A, Rosenfeld-Franklin M, Gibson NW, Miglarese M, Epstein D, Iwata KK, Haley JD.

Clin Exp Metastasis. 2008;25(6):685-93. doi: 10.1007/s10585-007-9121-7. Epub 2008 Jan 31. Review.

19.

Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents.

Califano R, Morgillo F, De Mello RA, Mountzios G.

Ann Transl Med. 2015 Apr;3(6):81. doi: 10.3978/j.issn.2305-5839.2015.03.44. Review.

20.

Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance.

Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, St John M, Sharma S, Dubinett SM.

J Thorac Oncol. 2008 Feb;3(2):107-10. doi: 10.1097/JTO.0b013e3181630ece. Review.

Items per page

Supplemental Content

Write to the Help Desk